Design of Energy-Efficient Artificial Noise for Physical Layer Security in Visible Light Communications

This paper studies the design of energy-efficient artificial noise (AN) schemes in the context of physical layer security in visible light communications (VLC). Two different transmission schemes termed $\textit{selective AN-aided single-input single-output (SISO)}$ and $\textit{AN-aided multiple-input single-output (MISO)}$ are examined and compared in terms of secrecy energy efficiency (SEE). In the former, the closest LED luminaire to the legitimate user (Bob) is the information-bearing signal's transmitter. At the same time, the rest of the luminaries act as jammers transmitting AN to degrade the channels of eavesdroppers (Eves). In the latter, the information-bearing signal and AN are combined and transmitted by all luminaries. When Eves' CSI is unknown, an indirect design to improve the SEE is formulated by maximizing Bob's channel's energy efficiency. A low-complexity design based on the zero-forcing criterion is also proposed. In the case of known Eves' CSI, we study the design that maximizes the minimum SEE among those corresponding to all eavesdroppers. At their respective optimal SEEs, simulation results reveal that when Eves' CSI is unknown, the selective AN-aided SISO transmission can archive twice better SEE as the AN-aided MISO does. In contrast, when Eves' CSI is known, the AN-aided MISO outperforms by 30%

New onset diabetes after transplantation (NODAT): an overview

Although renal transplantation ameliorates cardiovascular risk factors by restoring renal function, it introduces new cardiovascular risks including impaired glucose tolerance or diabetes mellitus, hypertension, and dyslipidemia that are derived, in part, from immunosuppressive medications such as calcineurin inhibitors, corticosteroids, or mammalian target of rapamycin inhibitors. New onset diabetes mellitus after transplantation (NODAT) is a serious and common complication following solid organ transplantation. NODAT has been reported to occur in 2% to 53% of all solid organ transplants. Kidney transplant recipients who develop NODAT have variably been reported to be at increased risk of fatal and nonfatal cardiovascular events and other adverse outcomes including infection, reduced patient survival, graft rejection, and accelerated graft loss compared with those who do not develop diabetes. Identification of high-risk patients and implementation of measures to reduce the development of NODAT may improve long-term patient and graft outcome. The following article presents an overview of the literature on the current diagnostic criteria for NODAT, its incidence after solid organ transplantation, suggested risk factors and potential pathogenic mechanisms. The impact of NODAT on patient and allograft outcomes and suggested guidelines for early identification and management of NODAT will also be discussed

Antithrombotic strategies in patients undergoing percutaneous coronary intervention for acute coronary syndrome

In patients undergoing percutaneous coronary intervention (PCI) for acute coronary syndrome (ACS), both periprocedural acute myocardial infarction and bleeding complications have been shown to be associated with early and late mortality. Current standard antithrombotic therapy after coronary stent implantation consists of lifelong aspirin and clopidogrel for a variable period depending in part on the stent type. Despite its well-established efficacy in reducing cardiac-related death, myocardial infarction, and stroke, dual antiplatelet therapy with aspirin and clopidogrel is not without shortcomings. While clopidogrel may be of little beneficial effect if administered immediately prior to PCI and may even increase major bleeding risk if coronary artery bypass grafting is anticipated, early discontinuation of the drug may result in insufficient antiplatelet coverage with thrombotic complications. Optimal and rapid inhibition of platelet activity to suppress ischemic and thrombotic events while minimizing bleeding complications is an important therapeutic goal in the management of patients undergoing percutaneous coronary intervention. In this article we present an overview of the literature on clinical trials evaluating the different aspects of antithrombotic therapy in patients undergoing PCI and discuss the emerging role of these agents in the contemporary era of early invasive coronary intervention. Clinical trial acronyms and their full names are provided in Table 1

Dynamic Physical-Layer Secured Link in a Mobile MIMO VLC System

This paper proposes a novel approach to provide a privately secured multiple-input and multiple-output visible light communication (VLC) in the mobility conditions. In the proposed system, a private secured VLC link is adaptively allocated to a mobile user all the time thanks to the movement tracking assistance by a camera-based detection system. The generation of the dynamic location-based scrambling matrix will be introduced providing a secured communication zone within a full normal coverage illumination area. An extensive range of numerical evaluation and practical experiments is carried out to demonstrate and evaluate the proposed system performance in different environment configurations including the mobility, camera resolutions, link range, and environment light intensity. We demonstrate that the proposed system is fully capable of securely steering the information with respect to a receiver location with a high level of reliability